Transgene consolidates its balance sheet thanks to the conversion of part of the advance into shares

Transgene, a biotechnology company specializing in cancer immunotherapies, announces the conversion of 32,999,999.57 euros of debt into shares. This operation, supported by its majority shareholder TSGH, a subsidiary of Institut Mérieux, increases TSGH's stake in Transgene's capital from 59.7% to 69.1%.

In September 2023, Transgene signed a current account advance agreement with TSGH for an initial amount of 36 million euros, increased to 66 million in March 2024. To date, 35.6 million euros have been fired. This conversion makes it possible to reduce the company's net debt.

The gross proceeds of the operation amount to 32,999,999.57 euros, intended to repay this advance. Transgene expects to have the necessary liquidity until the fourth quarter of 2025. This increased financial capacity will allow the company to continue developing its innovative immunotherapies.